EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar

Hiam Chemaitelly iD, Houssein H Ayoub iD, Peter Coyle, Patrick Tang, Mohammad R Hasan iD, Hadi M Yassine, Asmaa A Al Thani, Zaina Al-Kanaani, Einas Al-Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif und 10 weitere

Influenza and Other Respiratory Viruses · 2024

DOI: 10.1111/irv.13357 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Hiam Chemaitelly und 21 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. Hauptthemen laut MEDLINE: BNT162 Vaccine, COVID-19, 2019-nCoV Vaccine mRNA-1273, SARS-CoV-2. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Weill Cornell Medicine-Qatar, Ministry of Public Health, Hamad Medical Corporation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study provides a head‐to‐head comparison of the protection provided by the BNT162b2 and mRNA‐1273 vaccines against SARS‐CoV‐2 infection and against severe COVID‐19, covering primary series and third dose/booster vaccinations over up to 3 years of follow‐up, both before and after the emergence of the omicron variant.

Methods

Two national, matched, retrospective cohort studies were conducted on Qatar's vaccinated population from December 16, 2020, to February 18, 2024. Subgroup analyses by pre‐vaccination SARS‐CoV‐2 infection history, as well as sensitivity analyses, were also conducted.

Results

The adjusted hazard ratio (AHR) comparing infection incidence in those vaccinated with BNT162b2 versus mRNA‐1273 was 1.03 (95% CI: 1.02–1.05) after the primary series and 1.11 (95% CI: 1.09–1.13) after the third (booster) dose. The corresponding AHRs for any severe, critical, or fatal COVID‐19 were 1.31 (95% CI: 0.81–2.11) and 1.00 (95% CI: 0.20–4.94), respectively. Subgroup analyses by prior infection status hinted at a dose‐dependent immune imprinting effect, where a combination of two types of immunity, pre‐omicron and omicron, offered greater protection against infection than one type alone, with this effect being amplified by the higher antigen dose of mRNA‐1273 compared to BNT162b2. Sensitivity analyses confirmed the study findings.

Conclusions

BNT162b2 provided slightly less protection against infection than mRNA‐1273 following both primary series and booster vaccinations while offering comparable protection against severe COVID‐19 outcomes. The findings suggested that the vaccine antigen dose in interaction with infection history may determine the extent of immune protection against infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BNT162 VaccineCOVID-192019-nCoV Vaccine mRNA-1273SARS-CoV-2COVID-19 VaccinesHumansQatarRetrospective StudiesMaleAdultMiddle AgedFemaleYoung AdultVaccinationImmunization, SecondaryAdolescentAged

Stichwörter der Autor:innen

COVID‐19cohort studyepidemiologyimmune imprintingimmunityvaccine

Substanzen

BNT162 Vaccine2019-nCoV Vaccine mRNA-1273COVID-19 Vaccines

Autor:innen und Institutionen

  • Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - E…
  • Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, New York, USA.
  • Mathematics Program, Department of Mathematics and Statistics, College of Arts and Sciences, Qatar University, Doha, Qatar.
  • Department of Biomedical Science, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Hamad Medical Corporation, Doha, Qatar.

ORCID-Profile: Hiam Chemaitelly, Houssein H Ayoub, Mohammad R Hasan, Gheyath K Nasrallah, Laith J Abu-Raddad

Förderung

  • Weill Cornell Medicine-Qatar
  • Ministry of Public Health
  • Hamad Medical Corporation
  • Sidra Medicine
  • Qatar Genome Programme
  • Qatar University
  • Weill Cornell Medicine - Qatar

Zitieren

APA

Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Hasan, M. R., Yassine, H. M., Al Thani, A. A., Al-Kanaani, Z., Al-Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul-Rahim, H. F., Nasrallah, G. K., Al-Kuwari, M. G., Butt, A. A., Al-Romaihi, H. E., Al-Thani, M. H., …, & Abu-Raddad, L. J. (2024). BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.13357

Vancouver

Chemaitelly H, Ayoub HH, Coyle P, Tang P, Hasan MR, Yassine HM, et al. BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.13357

BibTeX
@article{Chemaitelly2024,
  author = {Chemaitelly, Hiam and Ayoub, Houssein H and Coyle, Peter and Tang, Patrick and Hasan, Mohammad R and Yassine, Hadi M and Al Thani, Asmaa A and Al-Kanaani, Zaina and Al-Kuwari, Einas and Jeremijenko, Andrew and Kaleeckal, Anvar Hassan and Latif, Ali Nizar and Shaik, Riyazuddin Mohammad and Abdul-Rahim, Hanan F and Nasrallah, Gheyath K and Al-Kuwari, Mohamed Ghaith and Butt, Adeel A and Al-Romaihi, Hamad Eid and Al-Thani, Mohamed H and Al-Khal, Abdullatif and Bertollini, Roberto and Abu-Raddad, Laith J},
  title = {BNT162b2 Versus mRNA‐1273 Vaccines: Comparative Analysis of Long‐Term Protection Against SARS‐CoV‐2 Infection and Severe COVID‐19 in Qatar},
  journal = {Influenza and Other Respiratory Viruses},
  year = {2024},
  doi = {10.1111/irv.13357}
}
Kostenlos starten →